DAISHIN CHEMICAL (4629) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Although revenue declined, this quarter was characterized by substantial profit growth, primarily driven by improvements in the cost and expense structure. Revenue declined to ¥25.89B (-2.0% YoY), while Operating Income increased significantly to ¥0.95B (+79.6%), Ordinary Income to ¥1.01B (+70.4%), and Net Income to ¥0.68B (+83.0%). Extraordinary gains and losses were negligible, and the primary drivers of profit growth were improvements in the cost-of-sales ratio and SG&A expense ratio at the operating level.

Factors Affecting Performance

【Revenue】Revenue was ¥25.89B, down 2.0% YoY. As the company operates in a single Chemicals Business segment, the decline appears to have been affected by lower demand or weakness in sales volume and pricing. Progress against the full-year forecast of ¥36.02B was 71.9%, slightly below the standard quarterly progress benchmark of approximately 75%.

【Profit and Loss】Cost of sales was ¥22.25B, resulting in a cost-of-sales ratio of 85.9%, an improvement from the prior-year ratio of 87.9%. Consequently, the gross profit margin rose to 14.1% from approximately 13.6% in the prior year, while SG&A expenses were ¥2.69B and the SG&A expense ratio was managed at 10.4%, broadly in line with the prior year. Non-operating income and expenses, including dividends received, lifted Ordinary Income by ¥0.055B, while extraordinary gains and losses remained negligible, indicating limited impact from temporary factors. The Net Income growth rate of +83.0% exceeded the Operating Income growth rate of +79.6% because the effective tax rate declined slightly from 32.9% in the prior year to 32.7%. In conclusion, the company achieved profit growth despite a revenue decline.

Segment Analysis

As the company operates in a single Chemicals Business segment, no segment-level disclosure is provided.

Key Financial Metrics

【Profitability】The Operating Income margin was 3.7% and the Net Income margin was 2.6%. Both improved from the same period of the prior year, although the absolute level of profitability remains limited. ROE was 4.0%, with the low Net Income margin serving as the primary constraint on ROE.【Cash Flow Quality】Accounts receivable were ¥8.33B, accounting for 31.8% of total assets, and receivables, including electronically recorded monetary claims, have been trending upward. Inventory was ¥0.32B, or only 1.2% of total assets, indicating limited inventory risk.【Investment Efficiency】Annualized total asset turnover was 0.987x, indicating that asset efficiency has remained broadly flat.【Financial Soundness】The Equity Ratio was 65.0%, the current ratio was 226.1%, and the quick ratio was 222.5%, all at high levels, indicating strong short-term payment capacity. Interest-bearing debt consisted solely of ¥0.30B in short-term borrowings, while cash and deposits of ¥6.61B substantially exceeded this amount.

Cash Flow Analysis

As cash flow statement figures are not included in the disclosed information, funding trends are assessed based on balance sheet movements. Cash and deposits declined to ¥6.61B from ¥7.13B in the prior year, while accounts receivable increased to ¥8.33B from ¥7.77B and electronically recorded monetary claims also increased, suggesting that some funds generated through operating activities may be tied up in receivables. Accounts payable were ¥4.71B and electronically recorded obligations were ¥3.08B, indicating that payables also increased and that cash inflows and outflows expanded on both sides of working capital. Inventory was small at ¥0.32B, limiting cash pressure from inventory. Property, plant and equipment was ¥3.83B, slightly down from ¥3.99B in the prior year, with no evidence of significant investment expansion. Overall, cash and deposits declined despite profit growth, so whether the increase in profit translated directly into cash generation should continue to be monitored, including the status of receivables collection.

Earnings Quality

The increase in Net Income was driven primarily by improvements at the Operating Income level rather than by extraordinary gains and losses, and earnings quality can therefore be viewed as recurring in nature. Extraordinary income of ¥0.002B and extraordinary losses of ¥0.001B were both negligible, with an immaterial impact on Net Income of ¥0.68B. Of ¥0.06B in non-operating income, dividends received amounted to ¥0.02B. Non-operating income made a certain contribution to Ordinary Income, although its scale was limited. Meanwhile, accounts receivable and electronically recorded monetary claims increased despite declining revenue, and annualized DSO reached 88 days. The relatively greater increase in the accrual component represented by trade receivables compared with profit growth on the income statement warrants attention when assessing the support provided by cash flow.

Earnings Forecasts and Guidance

As of the cumulative Q3 period, progress against the full-year forecast was 71.9% for Revenue, 96.4% for Operating Income, 96.1% for Ordinary Income, and 94.3% for Net Income. Progress for all profit-related metrics significantly exceeded the standard quarterly benchmark of approximately 75%, indicating a high likelihood of achieving the full-year forecasts, while Revenue progress was somewhat slower. The company has not revised either its earnings forecast or dividend forecast, and the amount of profit required in the remaining quarters is small: just under ¥0.05B for Operating Income and slightly more than ¥0.04B for Net Income. Whether Revenue reaches the full-year forecast remains a separate issue requiring confirmation, irrespective of the strong profit progress.

Shareholder Returns

The Q2 dividend was ¥0, while the full-year dividend forecast is ¥40 per share. Based on forecast full-year EPS of ¥157.37, the Payout Ratio is 25.4%, representing a conservative dividend burden relative to earnings and remaining below 60%. Cumulative Q3 EPS was ¥148.59, reaching 94.4% of the full-year forecast, strengthening the earnings support for the dividend forecast. No information regarding share repurchases has been disclosed; accordingly, the assessment is based solely on the dividend Payout Ratio.

Risk Factors

1. Prolonged collection period for accounts receivable: Annualized DSO was 88 days, and accounts receivable of ¥8.33B accounted for 31.8% of total assets. With receivables increasing despite declining revenue, a deterioration in collection efficiency could affect cash flow quality.

2. Low gross margin structure: Although the gross profit margin has improved to 14.1%, the Chemicals Business remains structurally vulnerable to renewed margin pressure if increases in raw material prices and energy costs cannot be passed through to customers.

3. Reliance on short-term borrowings: Interest-bearing debt of ¥0.30B consists entirely of short-term borrowings, resulting in a short-term debt ratio of 100%. Although cash and deposits of ¥6.61B provide ample coverage and near-term liquidity risk is limited, refinancing terms should be monitored continuously.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

Although the company’s profitability improved from the prior year, it remains below the manufacturing industry median.

Growth and Capital Efficiency

Revenue growth was below the industry median, confirming that the company is in a phase of profit improvement without accompanying revenue growth.

※Source: Compiled by the Company

Key Points from the Earnings Results

1. Substantial profit growth despite declining revenue indicates the emergence of operating leverage through improvements in the cost-of-sales ratio and SG&A expense ratio. As profit improvement has not been accompanied by revenue growth, its sustainability will depend on future pricing power and trends in raw material costs.

2. Progress against the full-year forecast for profit—96.4% for Operating Income and 94.3% for Net Income—significantly exceeded the standard progress benchmark. While the likelihood of achieving the full-year forecast is high, the Revenue progress rate of 71.9% remains a point of attention.

3. The financial foundation is sound, with an Equity Ratio of 65.0% and a current ratio of 226.1%. However, the extension of DSO to 88 days due to increases in accounts receivable and electronically recorded monetary claims should be monitored to assess the extent to which profit growth is translating into cash generation.

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not constitute a recommendation to invest in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 earnings were materially stronger despite a 2.0% year-on-year decline in cumulative revenue, driven by a sharp recovery in gross profitability. Revenue was ¥25.889bn, while operating income increased 79.6% year on year to ¥0.954bn. Ordinary income rose 70.4% to ¥1.009bn. Net income increased 83.0% to ¥0.679bn, equivalent to EPS of ¥148.59. Gross profit increased to ¥3.643bn from ¥3.203bn in the prior-year period despite lower sales. The gross margin improved to 14.1% from 12.1%, an expansion of approximately 194 basis points. SG&A expense was broadly flat year on year at ¥2.688bn, increasing only 0.6%. As a result, the SG&A-to-sales ratio was essentially unchanged at about 10.4%, and gross-margin recovery translated efficiently into operating-profit growth. Operating margin expanded to 3.7% from 2.0%, a 168bp improvement. Net margin improved to 2.6% from 1.4%, or roughly 122bp. The earnings recovery was primarily operational rather than driven by financial income, as non-operating income was only ¥0.063bn, including ¥0.021bn of dividend income. Small extraordinary gains and losses had a negligible net effect on reported earnings. The balance sheet remains highly liquid, with ¥6.614bn of cash and deposits against only ¥0.300bn of short-term loans. Management's unchanged full-year forecast implies that Q3 has already captured most of the expected annual operating and net profit. Specifically, Q3 progress against full-year guidance is 71.9% for sales, 96.4% for operating income, 96.1% for ordinary income, and 94.4% for net income. This creates an unusually back-end-light earnings profile, with implied Q4 operating income of only about ¥0.036bn. The key forward issue is whether the improved gross margin can be maintained while revenue returns to growth. Receivable collection efficiency and the low absolute margin structure remain important constraints on the quality and resilience of returns.

Profitability Analysis

The reported annualized DuPont ROE is 5.3%, comprising a 2.6% net profit margin, 1.316x asset turnover, and 1.54x financial leverage. The net-profit margin is the principal constraint on shareholder returns, remaining below the 3% threshold despite substantial year-on-year improvement. The operating-margin improvement from 2.0% to 3.7% was the dominant positive change in the earnings model. Gross margin rose 194bp to 14.1%, demonstrating that the operating-income recovery was driven chiefly by a lower cost-of-sales ratio rather than sales growth. SG&A rose only 0.6% versus the 2.0% decline in sales, implying modest negative operating leverage at the expense-ratio level; however, the gross-profit increase more than offset this effect. The operating margin of 3.7% remains below the 5% efficiency benchmark and is the central profitability concern identified by the quality alert. The gross margin of 14.1% is also below the 20% reference level, leaving earnings sensitive to procurement costs, selling-price discipline, and product mix. The five-factor analysis shows a tax burden of 0.672 and an interest burden of 1.058, confirming that interest costs are immaterial and that financial expenses do not constrain earnings. Interest coverage is exceptionally strong at 590.71x. Financial leverage is moderate rather than aggressive, and the company is not relying on debt to generate its return profile. Annualized ROA is approximately 3.5%, based on annualized Q3 net income and average total assets, while annualized ROE is around the reported 5.3%; both remain below the stated return benchmarks. Accordingly, further sustainable ROE improvement depends primarily on lifting operating and net margins rather than increasing leverage.

Growth Assessment

Top-line momentum remains soft, with Q3 cumulative revenue declining 2.0% year on year to ¥25.889bn. In contrast, operating income grew 79.6%, indicating that the earnings improvement was generated through margin recovery rather than volume-led expansion. Gross profit increased 13.7% year on year, substantially outperforming sales. The unchanged full-year forecast calls for revenue of ¥36.020bn, up 3.8% year on year, operating income of ¥0.990bn, up 23.9%, and ordinary income of ¥1.050bn, up 20.0%. Q3 revenue progress of 71.9% is modestly below the standard 75% Q3 run rate, whereas operating-profit progress of 96.4% is 21.4 percentage points above it. Net-income progress of 94.4% is likewise 19.4 percentage points ahead of the standard run rate. The guidance profile implies Q4 revenue of approximately ¥10.131bn but operating income of only ¥0.036bn and net income of approximately ¥0.040bn. This forecast shape indicates that management expects materially lower profitability in Q4 than achieved cumulatively through Q3. Sustained growth therefore requires confirmation that the gross-margin gains are not temporary and can coexist with a return to positive revenue growth. The company operates in a single chemical-products segment, so overall earnings are concentrated in one business and product-market cycle. For a chemical manufacturer, input-cost volatility, customer pricing negotiations, and demand fluctuations across industrial end markets are the principal variables that can affect margin durability.

Financial Health

Financial health is strong from a liquidity and debt-service perspective. Current assets of ¥20.346bn exceed current liabilities of ¥9.000bn, producing a current ratio of 226.1% and a quick ratio of 222.5%. Working capital is ¥11.346bn. Cash and deposits total ¥6.614bn, equal to 25.2% of total assets. Interest-bearing debt consists of ¥0.300bn of short-term loans, and cash covers this amount by 22.05x. Debt/capital is only 1.7%, while the reported debt-to-equity ratio is 0.54x; the balance sheet is therefore conservatively financed in practical interest-bearing-debt terms. The refinancing-risk alert arises because 100% of interest-bearing debt is short term, but its absolute amount is small relative to cash, current assets, and annualized earnings capacity. There is no material maturity mismatch: current assets exceed current liabilities by ¥11.346bn and cash alone substantially exceeds short-term borrowings. Total equity increased to ¥17.059bn from ¥16.520bn a year earlier, supported by retained earnings growth to ¥15.214bn. The equity ratio is approximately 65.0%, providing a substantial capital buffer. Intangible assets increased from ¥0.061bn to ¥0.274bn, up 350.1%, although they remain only 1.0% of total assets and therefore do not presently create a material balance-sheet concentration. Inventories increased 46.5% to ¥0.323bn; while modest at 1.2% of assets, this movement should be monitored for alignment with sales demand and product turnover. Trade receivables rose to ¥8.329bn, and electronically recorded operating claims were ¥4.087bn, underscoring the importance of disciplined collection management.

Notable B/S Changes

Intangible assets: +¥0.213bn (+350.1%) to ¥0.274bn - a large percentage increase from a small base; intangible assets remain only 1.0% of total assets, limiting current balance-sheet concentration. Inventories: +¥0.103bn (+46.5%) to ¥0.323bn - inventory rose while revenue declined 2.0%; monitor turnover and demand alignment, although the reported inventory balance is only 1.2% of total assets.

Cash Flow Quality

The reported cash balance is robust at ¥6.614bn and materially exceeds short-term loans of ¥0.300bn. However, earnings cash-conversion quality cannot be quantified from the available period information because operating cash flow, investing cash flow, financing cash flow, and capital expenditure figures are not reported. The principal working-capital quality issue is the quality alert for receivable days of 88 days on an annualized basis, above both the 60-day warning threshold and the 45-day manufacturing efficiency benchmark. Elevated receivable days increase the amount of capital tied up in customer credit and can delay conversion of reported revenue into cash. This is particularly relevant because revenue declined 2.0% while trade receivables increased to ¥8.329bn. Electronic receivables of ¥4.087bn are also significant and reinforce the need to monitor the total customer-credit cycle. Accounts payable were ¥4.712bn and electronically recorded obligations were ¥3.081bn, providing meaningful supplier financing within the operating cycle. Finished-goods inventory was ¥0.323bn, and the reported inventory balance remains low relative to assets. The increase in inventories should nevertheless be assessed against future shipment trends, especially if revenue remains subdued. With no cash-flow data, free-cash-flow coverage of dividends and reinvestment cannot be determined quantitatively.

Dividend Sustainability

The full-year dividend forecast is ¥40.00 per share, with no revision disclosed. Based on forecast EPS of ¥157.37, the implied dividend payout ratio is approximately 25.4%. This is comfortably below the 60% sustainability benchmark. Based on Q3 EPS of ¥148.59, the planned annual dividend represents about 26.9% of cumulative earnings per share. Retained earnings of ¥15.214bn and cash and deposits of ¥6.614bn provide substantial balance-sheet support for the planned distribution. The absence of material interest-bearing debt further supports financial flexibility. The company has not disclosed a Q2 dividend payment, consistent with the stated ¥0 interim DPS. Dividend sustainability is therefore supported by earnings, retained capital, and liquidity. The principal determinant of longer-term dividend capacity is the durability of the recent gross-margin recovery, given the low 3.7% operating margin and implied weaker Q4 profitability under full-year guidance.

Risk Assessment

Business risks include Chemical-products demand risk: the single-segment business structure concentrates exposure to industrial demand conditions and customer purchasing cycles., Margin risk: the 14.1% gross margin and 3.7% operating margin leave profitability exposed to raw-material cost inflation, energy costs, freight costs, and selling-price pressure., Working-capital risk: annualized receivable days of 88 exceed the 60-day warning threshold, increasing exposure to slower customer collections and potential cash-conversion volatility., Inventory and demand-matching risk: inventories increased 46.5% year on year while revenue declined 2.0%, requiring monitoring of stock rotation and demand alignment., Environmental and regulatory risk: as a chemical manufacturer, the group is exposed to environmental compliance, handling standards, waste-management requirements, and potential remediation costs..

Financial risks include Short-term refinancing risk: 100% of interest-bearing debt is short term, although the ¥0.300bn debt balance is modest and covered 22.05x by cash., Low-return risk: annualized ROE of 5.3% and annualized ROA of approximately 3.5% remain below reference return thresholds despite the earnings rebound., Forecast-execution risk: operating-profit progress is already 96.4% of full-year guidance at Q3, implying a very low Q4 operating-profit contribution and limited room for operational disruption..

Key concerns include LOW_OPERATING_EFFICIENCY: EBIT margin of 3.7% is below the 5% benchmark. The improvement is substantial, but the business remains vulnerable to relatively small cost or price changes., REFINANCING_RISK: the short-term debt ratio is 100%. This is structurally a maturity-concentration issue, though its practical impact is mitigated by ¥6.614bn of cash against ¥0.300bn of short-term loans., HIGH_RECEIVABLE_DAYS: annualized DSO of 88 days signals slow collection relative to manufacturing benchmarks and may weaken conversion of accounting profit into operating cash., LOW_GROSS_MARGIN: gross margin of 14.1% is below the 20% reference level. The 194bp year-on-year recovery is encouraging, but the low starting level means earnings sensitivity remains high..

Investment Implications

Key takeaways include Operating earnings recovered sharply: operating income rose 79.6% and net income rose 83.0% despite a 2.0% revenue decline., Gross-margin expansion of approximately 194bp was the principal driver of profit growth, while SG&A was effectively flat., Liquidity is substantial, with current and quick ratios above 220% and cash covering short-term loans by 22.05x., Return metrics remain modest, with a reported annualized ROE of 5.3% and EBIT margin of 3.7%., Q3 earnings have already reached more than 94% of full-year net-income guidance, implying limited Q4 profit under the unchanged forecast., Receivable days of 88 are the key operating-balance-sheet metric to monitor..

Metrics to watch include Gross margin and operating margin, particularly whether the Q3 gross-margin recovery can be sustained., Revenue growth relative to the full-year ¥36.020bn forecast., Trade receivables, electronically recorded claims, and annualized DSO., Inventory movement relative to sales and customer demand., Q4 profitability versus the implied ¥0.036bn operating-income contribution under full-year guidance., Short-term borrowing levels and the continued excess of cash over debt., Dividend execution relative to the ¥40.00 per-share full-year plan..

Regarding relative positioning, The company combines a strong liquidity profile and minimal interest-bearing debt with a low-margin chemical-manufacturing earnings model. Its Q3 margin recovery and cost discipline compare favorably with the weak revenue trend, but the 3.7% EBIT margin, 5.3% annualized ROE, and elevated receivable days indicate that operating efficiency and cash conversion remain more important than balance-sheet solvency.